NOTCH1 and Stroke: The SanBio study assessed the use of SB623 cells, which are allogenic modified BMSCs transiently transfected with the human Notch-1 intracellular domain, in a two-year, single-arm, open-label, uncontrolled study of 18 patients in a stable chronic phase after stroke (6–60 months post-stroke) [48].